<p>在一個充滿波動和地緣政治緊張局勢的一週，全球市場面臨新的挑戰，主要的美國股票指數因貿易擔憂而出現下跌。儘管出現這些波動，美國 GDP 增長的上調為投資者提供了一個積極的信號，突顯出尋求具有強大基本面的成長公司的潛在機會。在這種環境下，擁有高內部持股的股票尤其吸引人，因為它們通常表明公司運營和戰略願景最接近的人對公司的信心。</p>
<h3>全球內部持股高的十大成長公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>UTI (KOSDAQ:A179900)</td>
<td>24.7%</td>
<td>120.7%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>32%</td>
<td>78.8%</td>
</tr>
<tr>
<td>Modetour Network (KOSDAQ:A080160)</td>
<td>12.7%</td>
<td>41.8%</td>
</tr>
<tr>
<td>Loadstar Capital K.K (TSE:3482)</td>
<td>31%</td>
<td>23.6%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>34.8%</td>
<td>34.4%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>35%</td>
<td>73%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.9%</td>
<td>27.1%</td>
</tr>
<tr>
<td>FUNDINNOInc (TSE:462A)</td>
<td>33.4%</td>
<td>41.5%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>10.6%</td>
<td>63.7%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>48.7%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們快速成長的全球高內部持股公司的 829 只股票的完整列表。</p>
<p>讓我們深入探討一些篩選出的優質選擇。</p>
<h2>Aimed Bio (KOSDAQ:A0009K0)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Aimed Bio Inc. 專注於開發針對腦部疾病的治療解決方案，包括神經腫瘤和退行性疾病，市值約為 3.70 萬億韓元。</p>
<p><strong>運營：</strong> 該公司通過研究、開發、生產和銷售針對腦部疾病的抗體治療產品，產生了 207.1 億韓元的收入。</p>
<p><strong>內部持股：</strong> 34.4%</p>
<p><strong>收益增長預測：</strong> 每年 87.4%。</p>
<p>Aimed Bio 最近完成了 707.3 億韓元的首次公開募股，顯示出市場的強烈興趣。預計該公司將實現顯著增長，收入預計每年增長 31.9%，超過韓國市場的平均水平。預計收益將以每年 87.42% 的速度增長，預計在三年內實現盈利。儘管股價波動較大，且交易價格低於估計的公允價值 20.9%，但內部交易保持穩定，近期沒有顯著的買入或賣出活動。</p>
<ul>
<li>點擊這裏瞭解 Aimed Bio 的細微差別，查看我們的詳細分析未來增長報告。</li>
<li>我們最近的估值報告指出，Aimed Bio 股票在市場上可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/59f4bc68-dbed-48af-8bda-cbd666ae66fc/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/59f4bc68-dbed-48af-8bda-cbd666ae66fc/chart/ownership-breakdown"/></p>
<p>截至 2026 年 1 月 KOSDAQ:A0009K0 的持股結構</p>
<h2>Oscotec (KOSDAQ:A039200)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Oscotec Inc. 是一家生物技術公司，涉及藥物開發、功能材料和牙科骨移植材料業務，市值為 2 萬億韓元。</p>
<p><strong>運營：</strong> 公司的收入分為新藥業務部門 199.1 億韓元、醫療業務部門 18.4 億韓元、功能材料 4.0781 億韓元和食品業務 10.8 億韓元。</p>
<p><strong>內部持股：</strong> 12.7%</p>
<p><strong>收益增長預測：</strong> 每年 116.4%。</p>
<p>Oscotec 的增長潛力體現在其預計每年收入增長 78.2%，超過韓國市場平均水平。預計該公司將在三年內實現盈利，收益預計每年顯著增長 116.36%。儘管最近出現財務虧損和股價波動較大，Oscotec 的交易價格遠低於其估計的公允價值，且內部持股保持穩定，近期沒有顯著的買入或賣出活動。</p>
<ul>
<li>點擊這裏深入瞭解 Oscotec 的具體情況，查看我們的詳細增長預測報告。</li>
<li>在審查我們最新的估值報告後，Oscotec 的股價可能過於樂觀。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e1610900-f7d6-458a-aa37-9f8236dc7ec7/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e1610900-f7d6-458a-aa37-9f8236dc7ec7/chart/ownership-breakdown"/></p>
<p>截至 2026 年 1 月 KOSDAQ:A039200 的持股結構</p>
<h2>BHI (KOSDAQ:A083650)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> BHI 有限公司在全球範圍內開發、製造和供應發電設備，市值為 2.25 萬億韓元。</p>
<p><strong>運營：</strong> 公司的收入主要來自其機械與工業設備部門，產生了 656.37 億韓元的收入。</p>
<p><strong>內部持股：</strong> 34.4%</p>
<p><strong>收益增長預測：</strong> 每年 27.2%。</p>
<p>BHI 與 Red Post Energy 和 BASIC Equipment 的戰略聯盟旨在加速美國發電項目，利用 BHI 的製造和融資能力。這使 BHI 在數據中心和人工智能基礎設施推動的能源需求上升中具備增長潛力。儘管股價波動較大，過去一年收益顯著增長，預測顯示收入將繼續以每年 28.6% 的速度增長，超過市場平均水平。最近的收益報告顯示出顯著的利潤增長，反映出強勁的運營表現。</p>
<ul>
<li>解鎖我們對 BHI 股票分析的全面見解，查看此增長報告。</li>
<li>根據我們最近的估值報告，BHI 的交易價格似乎超出了其估計價值。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1f2fd2f7-0df0-48ba-a38a-2917c982559c/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1f2fd2f7-0df0-48ba-a38a-2917c982559c/chart/ownership-breakdown"/></p>
<p>截至 2026 年 1 月 KOSDAQ:A083650 的持股結構</p>
<h2>總結</h2>
<ul>
<li>點擊這裏深入瞭解 829 家快速成長的全球高內部持股公司的全貌。</li>
<li>尋找其他投資？探索 23 家領先量子計算公司的頂尖企業，它們正在引領下一代技術革命，並在量子算法、超導量子比特和前沿研究方面取得突破。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和盈利增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>

<p>在全球市場波動的一週，美國股指因貿易擔憂而下跌，但美國 GDP 增長的上調為投資者提供了機會。內部持股比例高的公司，如 Aimed Bio、Oscotec 和 BHI，顯示出高達 116% 的盈利增長預期。Aimed Bio 專注於腦部疾病治療，Oscotec 專注於藥物開發，而 BHI 則專注於發電設備，儘管市場波動，這些公司都顯示出強勁的基本面。內部持股比例表明對其戰略願景的信心，使它們成為有吸引力的投資選擇</p>

<p>In a week marked by volatility and geopolitical tensions, global markets have faced renewed challenges, with major U.S. stock indexes experiencing declines amid trade concerns. Despite these fluctuations, the upward revision of U.S. GDP growth offers a silver lining, underscoring potential opportunities for investors seeking growth companies with strong fundamentals. In this environment, stocks with high insider ownership can be particularly appealing as they often indicate confidence from those closest to the company’s operations and strategic vision.</p>
<div class="lb-trans"><p>在一個充滿波動和地緣政治緊張局勢的一週，全球市場面臨新的挑戰，主要的美國股票指數因貿易擔憂而出現下跌。儘管出現這些波動，美國 GDP 增長的上調為投資者提供了一個積極的信號，突顯出尋求具有強大基本面的成長公司的潛在機會。在這種環境下，擁有高內部持股的股票尤其吸引人，因為它們通常表明公司運營和戰略願景最接近的人對公司的信心。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership Globally</h3>
<div class="lb-trans"><h3>全球內部持股高的十大成長公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>UTI (KOSDAQ:A179900)</td>
<td>24.7%</td>
<td>120.7%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>32%</td>
<td>78.8%</td>
</tr>
<tr>
<td>Modetour Network (KOSDAQ:A080160)</td>
<td>12.7%</td>
<td>41.8%</td>
</tr>
<tr>
<td>Loadstar Capital K.K (TSE:3482)</td>
<td>31%</td>
<td>23.6%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>34.8%</td>
<td>34.4%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>35%</td>
<td>73%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.9%</td>
<td>27.1%</td>
</tr>
<tr>
<td>FUNDINNOInc (TSE:462A)</td>
<td>33.4%</td>
<td>41.5%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>10.6%</td>
<td>63.7%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>48.7%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>UTI (KOSDAQ:A179900)</td>
<td>24.7%</td>
<td>120.7%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>32%</td>
<td>78.8%</td>
</tr>
<tr>
<td>Modetour Network (KOSDAQ:A080160)</td>
<td>12.7%</td>
<td>41.8%</td>
</tr>
<tr>
<td>Loadstar Capital K.K (TSE:3482)</td>
<td>31%</td>
<td>23.6%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>34.8%</td>
<td>34.4%</td>
</tr>
<tr>
<td>KebNi (OM:KEBNI B)</td>
<td>35%</td>
<td>73%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.9%</td>
<td>27.1%</td>
</tr>
<tr>
<td>FUNDINNOInc (TSE:462A)</td>
<td>33.4%</td>
<td>41.5%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>10.6%</td>
<td>63.7%</td>
</tr>
<tr>
<td>CD Projekt (WSE:CDR)</td>
<td>29.7%</td>
<td>48.7%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 829 stocks from our Fast Growing Global Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們快速成長的全球高內部持股公司的 829 只股票的完整列表。</p>
</div><p>Let's dive into some prime choices out of the screener.</p>
<div class="lb-trans"><p>讓我們深入探討一些篩選出的優質選擇。</p>
</div><h2>Aimed Bio (KOSDAQ:A0009K0)</h2>
<div class="lb-trans"><h2>Aimed Bio (KOSDAQ:A0009K0)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Aimed Bio Inc. focuses on developing therapeutic solutions for brain diseases, including neuro-oncological and degenerative conditions, with a market cap of approximately ₩3.70 trillion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Aimed Bio Inc. 專注於開發針對腦部疾病的治療解決方案，包括神經腫瘤和退行性疾病，市值約為 3.70 萬億韓元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of ₩20.71 billion by researching, developing, producing, and selling antibody-based therapeutics for brain diseases.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過研究、開發、生產和銷售針對腦部疾病的抗體治療產品，產生了 207.1 億韓元的收入。</p>
</div><p><strong>Insider Ownership:</strong> 34.4%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 34.4%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 87.4% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 87.4%。</p>
</div><p>Aimed Bio recently completed a KRW 70.73 billion IPO, signaling strong market interest. The company is poised for significant growth, with revenue expected to increase by 31.9% annually, outpacing the Korean market's average. Earnings are forecasted to grow at an impressive 87.42% per year, with profitability anticipated in three years. Despite high share price volatility and trading below estimated fair value by 20.9%, insider transactions remain stable without substantial buying or selling activity recently.</p>
<div class="lb-trans"><p>Aimed Bio 最近完成了 707.3 億韓元的首次公開募股，顯示出市場的強烈興趣。預計該公司將實現顯著增長，收入預計每年增長 31.9%，超過韓國市場的平均水平。預計收益將以每年 87.42% 的速度增長，預計在三年內實現盈利。儘管股價波動較大，且交易價格低於估計的公允價值 20.9%，但內部交易保持穩定，近期沒有顯著的買入或賣出活動。</p>
</div><ul>
<li>Click here to discover the nuances of Aimed Bio with our detailed analytical future growth report.</li>
<li>Insights from our recent valuation report point to the potential overvaluation of Aimed Bio shares in the market.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏瞭解 Aimed Bio 的細微差別，查看我們的詳細分析未來增長報告。</li>
<li>我們最近的估值報告指出，Aimed Bio 股票在市場上可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/59f4bc68-dbed-48af-8bda-cbd666ae66fc/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/59f4bc68-dbed-48af-8bda-cbd666ae66fc/chart/ownership-breakdown"/></p>
<p>KOSDAQ:A0009K0 Ownership Breakdown as at Jan 2026</p>
<div class="lb-trans"><p>截至 2026 年 1 月 KOSDAQ:A0009K0 的持股結構</p>
</div><h2>Oscotec (KOSDAQ:A039200)</h2>
<div class="lb-trans"><h2>Oscotec (KOSDAQ:A039200)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Oscotec Inc. is a biotechnology company involved in drug development, functional materials, and dental bone graft material businesses, with a market cap of ₩2 trillion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Oscotec Inc. 是一家生物技術公司，涉及藥物開發、功能材料和牙科骨移植材料業務，市值為 2 萬億韓元。</p>
</div><p><strong>Operations:</strong> The company's revenue segments are comprised of the New Drug Business Division at ₩19.91 billion, the Medical Business Sector at ₩1.84 billion, Functional Materials at ₩407.81 million, and the Food Business at ₩1.08 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入分為新藥業務部門 199.1 億韓元、醫療業務部門 18.4 億韓元、功能材料 4.0781 億韓元和食品業務 10.8 億韓元。</p>
</div><p><strong>Insider Ownership:</strong> 12.7%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 12.7%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 116.4% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 116.4%。</p>
</div><p>Oscotec's growth potential is underscored by its forecasted revenue increase of 78.2% annually, outpacing the Korean market average. The company is expected to become profitable in three years, with earnings projected to grow significantly at 116.36% per year. Despite recent financial losses and high share price volatility, Oscotec trades well below its estimated fair value and maintains stable insider ownership without significant recent buying or selling activity.</p>
<div class="lb-trans"><p>Oscotec 的增長潛力體現在其預計每年收入增長 78.2%，超過韓國市場平均水平。預計該公司將在三年內實現盈利，收益預計每年顯著增長 116.36%。儘管最近出現財務虧損和股價波動較大，Oscotec 的交易價格遠低於其估計的公允價值，且內部持股保持穩定，近期沒有顯著的買入或賣出活動。</p>
</div><ul>
<li>Dive into the specifics of Oscotec here with our thorough growth forecast report.</li>
<li>Upon reviewing our latest valuation report, Oscotec's share price might be too optimistic.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 Oscotec 的具體情況，查看我們的詳細增長預測報告。</li>
<li>在審查我們最新的估值報告後，Oscotec 的股價可能過於樂觀。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/e1610900-f7d6-458a-aa37-9f8236dc7ec7/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/e1610900-f7d6-458a-aa37-9f8236dc7ec7/chart/ownership-breakdown"/></p>
<p>KOSDAQ:A039200 Ownership Breakdown as at Jan 2026</p>
<div class="lb-trans"><p>截至 2026 年 1 月 KOSDAQ:A039200 的持股結構</p>
</div><h2>BHI (KOSDAQ:A083650)</h2>
<div class="lb-trans"><h2>BHI (KOSDAQ:A083650)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> BHI Co., Ltd. develops, manufactures, and supplies power plant equipment globally, with a market cap of ₩2.25 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> BHI 有限公司在全球範圍內開發、製造和供應發電設備，市值為 2.25 萬億韓元。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its Machinery &amp; Industrial Equipment segment, generating ₩656.37 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其機械與工業設備部門，產生了 656.37 億韓元的收入。</p>
</div><p><strong>Insider Ownership:</strong> 34.4%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 34.4%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 27.2% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 27.2%。</p>
</div><p>BHI's strategic alliance with Red Post Energy and BASIC Equipment aims to accelerate U.S. power generation projects, leveraging BHI’s manufacturing and financing capabilities. This positions BHI for growth amid rising energy demand driven by data centers and AI infrastructure. Despite a volatile share price, earnings grew significantly over the past year, with forecasts indicating continued revenue growth of 28.6% annually, surpassing market averages. Recent earnings reports show substantial profit increases, reflecting strong operational performance.</p>
<div class="lb-trans"><p>BHI 與 Red Post Energy 和 BASIC Equipment 的戰略聯盟旨在加速美國發電項目，利用 BHI 的製造和融資能力。這使 BHI 在數據中心和人工智能基礎設施推動的能源需求上升中具備增長潛力。儘管股價波動較大，過去一年收益顯著增長，預測顯示收入將繼續以每年 28.6% 的速度增長，超過市場平均水平。最近的收益報告顯示出顯著的利潤增長，反映出強勁的運營表現。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of BHI stock in this growth report.</li>
<li>In light of our recent valuation report, it seems possible that BHI is trading beyond its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對 BHI 股票分析的全面見解，查看此增長報告。</li>
<li>根據我們最近的估值報告，BHI 的交易價格似乎超出了其估計價值。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1f2fd2f7-0df0-48ba-a38a-2917c982559c/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/1f2fd2f7-0df0-48ba-a38a-2917c982559c/chart/ownership-breakdown"/></p>
<p>KOSDAQ:A083650 Ownership Breakdown as at Jan 2026</p>
<div class="lb-trans"><p>截至 2026 年 1 月 KOSDAQ:A083650 的持股結構</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Gain an insight into the universe of 829 Fast Growing Global Companies With High Insider Ownership by clicking here.</li>
<li>Seeking Other Investments? Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 829 家快速成長的全球高內部持股公司的全貌。</li>
<li>尋找其他投資？探索 23 家領先量子計算公司的頂尖企業，它們正在引領下一代技術革命，並在量子算法、超導量子比特和前沿研究方面取得突破。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和盈利增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div>

3 Global Growth Companies With High Insider Ownership Expecting Up To 116% Earnings Growth

Simplywall

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

OncoSec Medical Incorporated

Mustang Bio

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 3 倍做空 - Direxion

AIM ImmunoTech Inc.

醫藥突破 ETF - ALPS

標普生物技術 ETF - SPDR

AIM IMMUNOTECH INC

Invesco Nasdaq Biotechnology ETF

2 倍做多納斯達克生物技術 ETF - ProShares

三家全球增長型公司擁有高內部持股，預計盈利增長可達 116%